Report Detail

Other Global Direct-acting Antiviral Drugs Market Size, Status and Forecast 2020-2026

  • RnM3946415
  • |
  • 10 April, 2020
  • |
  • Global
  • |
  • 90 Pages
  • |
  • QYResearch
  • |
  • Other

This report focuses on the global Direct-acting Antiviral Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Direct-acting Antiviral Drugs development in North America, Europe, China and India.

The key players covered in this study
AbbVie Inc.
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma

Market segment by Type, the product can be split into
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
India

The study objectives of this report are:
To analyze global Direct-acting Antiviral Drugs status, future forecast, growth opportunity, key market and key players.
To present the Direct-acting Antiviral Drugs development in North America, Europe, China and India.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-acting Antiviral Drugs are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 NS3/4A Protease Inhibitors
    • 1.4.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
    • 1.4.4 NS5A Inhibitors
    • 1.4.5 Non-Nucleoside NS5B Polymerase Inhibitors
  • 1.5 Market by Application
    • 1.5.1 Global Direct-acting Antiviral Drugs Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Ambulatory Surgical Centers
    • 1.5.5 Pharmacies
    • 1.5.6 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Direct-acting Antiviral Drugs Market Perspective (2015-2026)
  • 2.2 Direct-acting Antiviral Drugs Growth Trends by Regions
    • 2.2.1 Direct-acting Antiviral Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Direct-acting Antiviral Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Direct-acting Antiviral Drugs Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Direct-acting Antiviral Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Direct-acting Antiviral Drugs Players by Market Size
    • 3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Direct-acting Antiviral Drugs Market Concentration Ratio
    • 3.2.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2019
  • 3.3 Direct-acting Antiviral Drugs Key Players Head office and Area Served
  • 3.4 Key Players Direct-acting Antiviral Drugs Product Solution and Service
  • 3.5 Date of Enter into Direct-acting Antiviral Drugs Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2021-2026)

5 Direct-acting Antiviral Drugs Breakdown Data by Application (2015-2026)

  • 5.1 Global Direct-acting Antiviral Drugs Market Size by Application (2015-2020)
  • 5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Direct-acting Antiviral Drugs Market Size (2015-2020)
  • 6.2 Direct-acting Antiviral Drugs Key Players in North America (2019-2020)
  • 6.3 North America Direct-acting Antiviral Drugs Market Size by Type (2015-2020)
  • 6.4 North America Direct-acting Antiviral Drugs Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Direct-acting Antiviral Drugs Market Size (2015-2020)
  • 7.2 Direct-acting Antiviral Drugs Key Players in Europe (2019-2020)
  • 7.3 Europe Direct-acting Antiviral Drugs Market Size by Type (2015-2020)
  • 7.4 Europe Direct-acting Antiviral Drugs Market Size by Application (2015-2020)

8 China

  • 8.1 China Direct-acting Antiviral Drugs Market Size (2015-2020)
  • 8.2 Direct-acting Antiviral Drugs Key Players in China (2019-2020)
  • 8.3 China Direct-acting Antiviral Drugs Market Size by Type (2015-2020)
  • 8.4 China Direct-acting Antiviral Drugs Market Size by Application (2015-2020)

9 India

  • 9.1 India Direct-acting Antiviral Drugs Market Size (2015-2020)
  • 9.2 Direct-acting Antiviral Drugs Key Players in India (2019-2020)
  • 9.3 India Direct-acting Antiviral Drugs Market Size by Type (2015-2020)
  • 9.4 India Direct-acting Antiviral Drugs Market Size by Application (2015-2020)

10 Key Players Profiles

  • 10.1 AbbVie Inc.
    • 10.1.1 AbbVie Inc. Company Details
    • 10.1.2 AbbVie Inc. Business Overview and Its Total Revenue
    • 10.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
    • 10.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2015-2020))
    • 10.1.5 AbbVie Inc. Recent Development
  • 10.2 GSK
    • 10.2.1 GSK Company Details
    • 10.2.2 GSK Business Overview and Its Total Revenue
    • 10.2.3 GSK Direct-acting Antiviral Drugs Introduction
    • 10.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.2.5 GSK Recent Development
  • 10.3 Boehringer Ingelheim
    • 10.3.1 Boehringer Ingelheim Company Details
    • 10.3.2 Boehringer Ingelheim Business Overview and Its Total Revenue
    • 10.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
    • 10.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.3.5 Boehringer Ingelheim Recent Development
  • 10.4 Merck
    • 10.4.1 Merck Company Details
    • 10.4.2 Merck Business Overview and Its Total Revenue
    • 10.4.3 Merck Direct-acting Antiviral Drugs Introduction
    • 10.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.4.5 Merck Recent Development
  • 10.5 Novartis
    • 10.5.1 Novartis Company Details
    • 10.5.2 Novartis Business Overview and Its Total Revenue
    • 10.5.3 Novartis Direct-acting Antiviral Drugs Introduction
    • 10.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.5.5 Novartis Recent Development
  • 10.6 Beximco Pharmaceuticals
    • 10.6.1 Beximco Pharmaceuticals Company Details
    • 10.6.2 Beximco Pharmaceuticals Business Overview and Its Total Revenue
    • 10.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
    • 10.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.6.5 Beximco Pharmaceuticals Recent Development
  • 10.7 Roche
    • 10.7.1 Roche Company Details
    • 10.7.2 Roche Business Overview and Its Total Revenue
    • 10.7.3 Roche Direct-acting Antiviral Drugs Introduction
    • 10.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.7.5 Roche Recent Development
  • 10.8 Bristol-Myers Squibb Company
    • 10.8.1 Bristol-Myers Squibb Company Company Details
    • 10.8.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
    • 10.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
    • 10.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.8.5 Bristol-Myers Squibb Company Recent Development
  • 10.9 Gilead Sciences
    • 10.9.1 Gilead Sciences Company Details
    • 10.9.2 Gilead Sciences Business Overview and Its Total Revenue
    • 10.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
    • 10.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.9.5 Gilead Sciences Recent Development
  • 10.10 Janssen (Johnson & Johnson)
    • 10.10.1 Janssen (Johnson & Johnson) Company Details
    • 10.10.2 Janssen (Johnson & Johnson) Business Overview and Its Total Revenue
    • 10.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
    • 10.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.10.5 Janssen (Johnson & Johnson) Recent Development
  • 10.11 Vertex Pharmaceuticals
    • 10.11.1 Vertex Pharmaceuticals Company Details
    • 10.11.2 Vertex Pharmaceuticals Business Overview and Its Total Revenue
    • 10.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
    • 10.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.11.5 Vertex Pharmaceuticals Recent Development
  • 10.12 Natco Pharma
    • 10.12.1 Natco Pharma Company Details
    • 10.12.2 Natco Pharma Business Overview and Its Total Revenue
    • 10.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
    • 10.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2015-2020)
    • 10.12.5 Natco Pharma Recent Development

11 Analyst's Viewpoints/Conclusions

    12 Appendix

    • 12.1 Research Methodology
      • 12.1.1 Methodology/Research Approach
      • 12.1.2 Data Source
    • 12.2 Disclaimer

    Summary:
    Get latest Market Research Reports on Direct-acting Antiviral Drugs. Industry analysis & Market Report on Direct-acting Antiviral Drugs is a syndicated market report, published as Global Direct-acting Antiviral Drugs Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Direct-acting Antiviral Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    3,131.70
    4,697.55
    6,263.40
    3,662.10
    5,493.15
    7,324.20
    602,706.00
    904,059.00
    1,205,412.00
    325,962.00
    488,943.00
    651,924.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report